Revolutionizing cervical cancer treatment: single-cell sequencing of TSPAN1+ tumor EPCs and immune checkpoints to assess drug sensitivity and optimize therapy
The immune landscape of cervical cancer and its interaction with tumor endothelial progenitor cells played crucial roles in determining the tumor's progression and response to therapy. The classification of tumor subtypes based on immune characteristics and drug sensitivity was critical for personalized treatment. The identification of <i>TSPAN1</i> as key biomarkers provided insight into tumor biology and potential therapeutic targets. Our findings emphasized the need for combining immune checkpoint modulation with precise drug sensitivity analysis to optimize treatment strategies, particularly in advanced cervical cancer.
Authors
- Zhikai Xiahou
- Zhiheng Lin (ORCID: https://orcid.org/0000-0002-9745-2286)
- Yumeng Li (ORCID: https://orcid.org/0000-0002-1073-4257)
- Zhijie Zhao (ORCID: https://orcid.org/0000-0001-5587-8855)
- Pingping Cai (ORCID: https://orcid.org/0009-0002-1517-5236)
- Guangyao Lin
Institutions
- Shandong University of Traditional Chinese Medicine (CN)
- Shanghai Ninth People's Hospital (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Longhua Hospital Shanghai University of Traditional Chinese Medicine (CN)
- Shandong Provincial Hospital (CN)
- China Institute of Sport Science (CN)
- Shandong First Medical University (CN)
- Beijing Sport University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1574174
- Citations
- 1
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 1.05